Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (223)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (636)
  2. Solid Tumor Oncology Division (636)
  3. Thoracic Oncology (636)
  4. Department of Pathology and Laboratory Medicine (208)
  5. GSK Faculty (189)
  6. Human Oncology and Pathogenesis Program (158)

More Groups

People
  1. Marc Ladanyi (122)
  2. Mark Kris (90)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (20)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (636)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II basket study of the oral TRK inhibitor LOXO-101 in adult subjects with NTRK fusion-positive tumors
    Meeting Abstract

    Drilon, A. E.; Hong, D. S.; Cruickshank, S.; Deegan, M.; Ku, N.; Hyman, D. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Drilon, A. E.; Camidge, D. R.; Ou, S. H. I.; Clark, J. W.; Socinski, M. A.; Weiss, J.; Riely, G. J.; Winter, M.; Wang, S. C.; Monti, K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase II basket study of the oral TRK inhibitor LOXO-101 in adult subjects with NTRK fusion-positive tumors
    Meeting Abstract

    Drilon, A.; Hong, D.; Deeken, J.; Smith, S.; Reynolds, M.; Cruickshank, S.; Deegan, M.; Ku, N.; Hyman, D.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors
    Meeting Abstract

    Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Martinez, E. J.; Makker, V.; Canziani, L.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits resistant NTRK kinase domain mutants
    Meeting Abstract

    Drilon, A.; Hofmann, N.; Flynn, D.; Smith, B.; Davare, M.
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors
    Meeting Abstract

    Drilon, A.; Marwan, F.; Fu, S.; Patel, M. R.; Olszanski, A. J.; Lockhart, A. C.; Liu, S. V.; Bazhenova, L.; Seery, T.; Nikolinakos, P.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Overcoming drug resistance to Trk inhibition by rational combination of entrectinib and trametinib: From bench to bedside
    Meeting Abstract

    Ho, A.; Wei, G.; Maneval, E. C.; Esquibel, V.; Berger, M. F.; Haque, S.; Patel, R.; Walsh, C.; Hornby, Z.; Multani, P.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Journal Article

    Drilon, A.; Rekhtman, N.; Arcila, M.; Wang, L.; Ni, A.; Albano, M.; Van Voorthuysen, M.; Somwar, R.; Smith, R. S.; Montecalvo, J.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save
  • Detection of ALK alternative transcription initiation and MET exon 14 skipping using nanoString digital nCounter technology in a clinical setting
    Meeting Abstract

    Borsu, L.; Mullaney, K.; Benayed, R.; Chi, P.; Busam, K.; Paik, P.; Drilon, A.; Ladanyi, M.
    Journal of Molecular Diagnostics (2016)

    Fulltext@MSK | Save
  • The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials
    Journal Article

    Li, B. T.; Barnes, T. A.; Chan, D. L.; Naidoo, J.; Lee, A.; Khasraw, M.; Marx, G. M.; Kris, M. G.; Clarke, S. J.; Drilon, A.; more...
    Lung Cancer (2016)

    Fulltext@MSK | Save